Clobetasol propionate
Clobetasol propionate is a corticosteroid used to treat skin conditions such as eczema, contact dermatitis, seborrheic dermatitis, and psoriasis. It is applied to the skin as a cream, ointment, or shampoo. Use should be short term and only if other weaker corticosteroids are not effective. Use is not recommended in rosacea or perioral dermatitis.
Clinical data | |
---|---|
Pronunciation | /kloʊˈbeɪtəsɒl/ |
Trade names | Dermovate, Temovate, Clovate, others |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | Topical |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.042.380 |
Chemical and physical data | |
Formula | C25H32ClFO5 |
Molar mass | 466.97 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
| |
(verify) |
Common side effects include skin irritation, dry skin, redness, pimples, and telangiectasia. Serious side effects may include adrenal suppression, allergic reactions, cellulitis, and Cushing's syndrome. Use in pregnancy and breastfeeding is of unclear safety. Clobetasol is believed to work by activating steroid receptors.
Clobetasol propionate was patented in 1968 and came into medical use in 1978. It is available as a generic medication. In 2021, it was the 162nd most commonly prescribed medication in the United States, with more than 3 million prescriptions.